Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research
Abstract
Objectives: Vortioxetine, has already shown its efficacy in the acute and long-term treatment of MDD, and its interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding cognitive effects of vortioxetine. Methods: We conducted a review of key data obtained from preclinical behavioral models and clinical trials in MDD focusing on vortioxetine-induced cognitive changes. Results: In animal, acute and chronic administration of vortioxetine improved performance on objective measures that cover a broad range of cognitive domains. In human, vortioxetine appears as a useful treatment option in patients with MDD, especially in the presence of cognitive dysfunction. Conclusion: Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still need to be determined.
Read the paper
Related studies
- Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial
- Nutritional, Physical, Cognitive, and Combination Interventions and Frailty Reversal Among Older Adults: A Randomized Controlled Trial
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- A randomized, controlled trial of oral propranolol in infantile hemangioma
- Clinical phenotypes of delirium during critical illness and severity of subsequent long-term cognitive impairment: a prospective cohort study
- Increased physical activity improves sleep and mood outcomes in inactive people with insomnia: a randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.